drug_type
RELEVANT_DRUG
intervention_type
Drug
drug_description
An intravenously administered antibody–drug conjugate (ADC) targeting folate receptor alpha (FRα). A monoclonal antibody binds FRα on tumor cells, undergoes FRα-mediated endocytosis, and releases an intracellular cytotoxic payload to induce tumor cell death. Intended for FRα-positive advanced solid tumors (e.g., ovarian, endometrial, lung adenocarcinoma, triple-negative breast cancer, PDAC, mesothelioma).
nci_thesaurus_concept_id
C190686
nci_thesaurus_definition
An antibody-drug conjugate (ADC) composed of a monoclonal antibody targeting folate receptor alpha (FRa; FolRa; FOLR1) conjugated to an as of yet undisclosed cytotoxic agent, with potential antineoplastic activity. Upon administration of anti-FRa ADC AMT-151, the antibody moiety targets and binds to FRa expressed on tumor cells. Upon cellular uptake and internalization, the cytotoxic agent inhibits tumor cell proliferation through an as of yet undisclosed mechanism of action (MoA). FRa is a glycosylphosphatidylinositol linked cell-surface glycoprotein that is widely expressed in certain cancers while its expression is limited in normal tissues.
drug_category
ANTIBODY DRUG CONJUGATE
drug_class
Conjugate
drug_delivery_route
Intravenous
drug_mechanism_of_action
Monoclonal antibody binds folate receptor alpha (FRα) on tumor cells, undergoes receptor-mediated endocytosis, and releases an intracellular cytotoxic payload (mechanism unspecified) to kill the cancer cell.
drug_name
AMT-151
nct_id_drug_ref
NCT05498597